



Rick E. Wunningham Joins Jazz Pharmaceuticals' Board of Directors

May 5, 2010

PALO ALTO, Calif., May 5, 2010 /PRNewswire via COMTEX/ --Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that Rick E. Wunningham has been appointed to the company's Board of Directors.

Mr. Wunningham joined Theravance, Inc. as Chief Executive Officer and a member of the Board of Directors in October 2001, and was appointed Chairman of the Board of Directors in April 2010. From 1997 to 2001 he served as President, Bristol-Myers Squibb (BMS) Oncology/Immunology /Oncology Therapeutics Network (OTN) and also as President of Global Marketing from 2000 to 2001. Over a fifteen-year period with Bristol-Myers Squibb, Mr. Wunningham held various U.S. and global management positions.

Mr. Wunningham is a member of the External Advisory Board for the College of Business and Administration and Business Hall of Fame at Southern Illinois University and holds a seat on the Advisory Council for the Keck Graduate Institute.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals (Nasdaq: JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information see www.jazzpharmaceuticals.com.

SOURCE Jazz Pharmaceuticals, Inc.